Recovery-Focused Compounds —
What to Use and When
The tissue repair category has more compounds and more mechanistic overlap to navigate than any other. This guide cuts through it — what each compound does, when to use it alone, and when to combine.
At a Glance
Every compound in the tissue repair category operates through a distinct biological mechanism. No two overlap completely — which is why combinations are so common in the literature.
Angiogenesis
BPC-157 — new blood vessel formation via VEGF/eNOS. Restores blood supply to ischemic and injured tissue.
Actin Regulation
TB-500 — G-actin sequestration driving cell migration systemically toward injury sites regardless of injection location.
Collagen Synthesis
GHK-Cu — fibroblast activation, collagen type I/III and elastin upregulation, copper-dependent enzyme activation.
NF-κB Inhibition
KPV — direct NF-κB blockade reducing IL-1β, IL-6, TNF-α. Targeted anti-inflammatory without systemic immunosuppression.
Antimicrobial / Innate Immune
LL-37 — membrane disruption against antibiotic-resistant bacteria and biofilms. Coordinates innate immune response and wound healing.
T-Cell / Adaptive Immune
Thymosin Alpha-1 — thymic peptide driving T-cell maturation and dendritic cell activation. Approved in 37+ countries.
EPO-Derived Cytoprotection
ARA-290 — innate repair receptor (βcR) activation for neuroprotection and organ cytoprotection without erythropoiesis.
Gene Expression
GHK-Cu's secondary dimension — modulation of 4,000+ human genes affecting antioxidant, anti-fibrotic, and repair networks.
Start here. These two have the deepest evidence bases in the category (100+ and 80+ studies respectively) and cover the two primary axes of tissue repair research. Most other combinations build on top of them.
The benchmark. Multi-pathway: angiogenesis, cytoprotection, GH receptor upregulation, anti-inflammatory. Oral bioavailability confirmed. Effective across tendon, gut, CNS, muscle, bone.
Full overview →The systemic complement. Actin-mediated cell mobilization from anywhere in the body toward the injury site. Works even when injected away from the injury.
Full overview →| Use Case | Compound |
|---|---|
| Single-site localized injury, gut/GI research, oral protocol designs | BPC-157 alone |
| Multi-site injury, systemic recovery models, when local injection isn't feasible | TB-500 alone |
| Maximum repair coverage — local + systemic simultaneously | Both (Wolverine Stack) |
| Stack | Best Research Use Case | Key Addition |
|---|---|---|
| Wolverine Stack (BPC-157 + TB-500) | Musculoskeletal, tendon, ligament, multi-site soft tissue | Systemic cell mobilization (TB-500) |
| GLOW Mix (+ GHK-Cu) | Wound healing quality, skin aging, connective tissue remodeling | Matrix structural proteins + gene expression layer |
| Klow Mix (KPV + BPC + GHK-Cu) | IBD, gut barrier, chronic skin inflammation, mucosal repair | NF-κB anti-inflammatory lead; fully oral possible |
AHK-Cu — Hair & Follicle Research: When hair follicle biology is the specific research target. AHK-Cu's dermal papilla affinity and Wnt/β-catenin activation distinguishes it from GHK-Cu's broader skin effects.
Thymosin Alpha-1 — Adaptive Immune & Viral Research: When immune modulation at the T-cell and dendritic cell level is the research objective — viral models, cancer immunotherapy adjuvant research, or immunodeficiency models. Approved in 37+ countries.
LL-37 — Antimicrobial Resistance & Wound Infection: When the research involves antibiotic-resistant pathogens, biofilm disruption, or wound infection models. LL-37 is the only human cathelicidin — it bridges pathogen clearance and wound healing in a single compound.
ARA-290 — Neuropathic Pain & Organ Cytoprotection: When EPO-derived cytoprotection without erythropoiesis is the research objective. Phase 2 data specifically in small fiber neuropathy — the only compound with published nerve fiber regeneration data in this indication.
Choosing between compounds for the same injury type? The key question is whether local, systemic, or matrix-level coverage is the priority. BPC-157 = local. TB-500 = systemic. GHK-Cu = matrix quality. KPV = inflammation control.
All compounds listed are for laboratory research use only. Not for human or veterinary use. Information based on publicly available scientific literature as of 2026. · Helixera Labs LLC © 2026